Kanne AM, et al. - Authors evaluated the serum levels of high mobility group box chromosomal protein 1 (HMGB-1) and the soluble receptor for advanced glycation end products (sRAGE) in patients with Sjogren's syndrome (SS) and explored correlations with disease activity. They assessed the disease activity using the European League Against Rheumatism SS Disease Activity Index (ESSDAI). Compared to healthy controls, serum levels of total HMGB-1 and sRAGE were elevated in patients with SS and correlated with disease activity as measured by the ESSDAI. High serum levels of HMGB-1 were seen in patients with extraglandular involvement.